blog-icon

Clinical research blog

Explore our blog for insights into the big questions in precision medicine and clinical research.

Exploring the future of genomics in healthcare: Early detection and prevention strategies for at-risk populations

Genomics has come a long way since the first human genome was sequenced in 2003. Today, sequencing a genome is not only faster but also significantly more affordable, thanks to advancements from industry leaders like Illumina and Oxford Nanopore. This progress has opened new avenues for research and precision medicine, particularly in identifying and supporting at-risk populations.

Continue reading

Webinar recap: Light The Way: Lessons learned from a genetic testing, education, and support platform

In this webinar, "Light The Way: Lessons learned from a genetic testing, education, and support platform," Paul Wicks shares an in-depth update on the “Light the Way” programme. He explores the methodologies used, the challenges addressed, and the progress made to-date in supporting individuals with genetic forms of motor neurone disease (MND), also known as amyotrophic lateral sclerosis (ALS). 

Continue reading

The Genetics Podcast recap: Exploring the microbiome's influence on personalised medicine with Almut Heinken

In the latest episode of The Genetics Podcast, Sano CEO Patrick Short had the pleasure of speaking with Almut Heinken, a junior professor at the INSERM Institute of Nutrition, Genetics, Environment, and Risk Exposure at Université de Lorraine. Almut’s fascinating research sits at the intersection of the microbiome, human genetics, drug discovery, and pharmacogenomics.

Continue reading

Webinar recap: Alpha-1 Antitrypsin Deficiency engagement, screening, and retention

In this webinar, "Alpha-1 Antitrypsin Deficiency: Engagement, screening, and retention," Sano Senior Project Manager, Hayley Holt, shares a case study on our work with an industry-leading sponsor to deliver genetically-qualified volunteers for a precision medicine clinical trial focused on Alpha-1 Antitrypsin Deficiency (AATD). The webinar explores the methodologies used and describes the success of the project.

Continue reading

The Genetics Podcast recap: Championing diversity and accessibility in genomics with Mavis Machirori

In the latest episode of the Genetics Podcast, Sano CEO Patrick Short had the pleasure of speaking with Mavis Machirori, a senior researcher at the Ada Lovelace Institute and co-founder of Genetics Engage

Continue reading

Navigating FDA guidance on natural history studies

Developing treatments for rare diseases involves unique obstacles due to the rarity and complexity of these conditions. To address these challenges, the FDA offers guidance on conducting natural history studies. These studies are essential for comprehending disease progression, identifying patient subgroups, discovering biomarkers, and refining clinical outcome assessments – all of which enhance the effectiveness and design of clinical trials.

Continue reading

Passion and purpose: Celebrating Clinical Trials Day at Sano

In honour of Clinical Trials Day, we're sharing some reflections from our team at Sano about why we do what we do. Clinical Trials Day marks the anniversary of James Lind's first controlled clinical trial in 1747, a key moment in medical history. For us at Sano, it’s a chance to celebrate the work we’re passionate about and the incredible people who make it possible. These quotes reflect some of our personal journeys and the reasons why we’re dedicated to advancing precision medicine. From living with genetic conditions to striving for groundbreaking discoveries, our team’s stories show the heart and commitment behind our mission to transform healthcare.

Continue reading

Understanding disease progression: The power of natural history studies

Natural history studies are essential for advancing our understanding of diseases, especially rare conditions with limited research. These studies monitor disease progression in their natural, untreated forms, providing invaluable insights that inform the development of effective treatments and precision medicine.

Continue reading

Exploring natural history studies in drug development

Natural history studies are vital for understanding disease progression, particularly in rare diseases. They provide a baseline to evaluate the effectiveness of new treatments. Our latest whitepaper explores the benefits and challenges associated with these studies.

Continue reading

Legal landscapes in precision medicine: Market access and intellectual property law [webinar recap]

This webinar is the second in a series on the complex legal environment of precision medicine, featuring Mina Frost, General Counsel for Sano Genetics. In this episode, Mina focuses on issues like market access, reimbursement, and intellectual property. Mina provides a clear breakdown of these topics, helping us understand how laws affect the delivery of innovative medical treatments.

Continue reading